杭州浙大迪迅生物基因工程有限公司JACI：宠物过敏治疗的新思路
发布日期：2019-05-17
原标题：对猫进行免疫，以诱导针对人类主要猫过敏原Fel d1的中和抗体
延伸阅读
JACI
DOI: https://doi.org/10.1016/j.jaci.2019.01.050
Background
Cat allergy in human subjects is usually caused by the major cat allergen Fel d 1 and is found in approximately 10% of the Western population. Currently, there is no efficient and safe therapy for cat allergy available. Allergic patients usually try to avoid cats or treat their allergy symptoms.
Objective
We developed a new strategy to treat Fel d 1–induced allergy in human subjects by immunizing cats against their own major allergen, Fel d 1.
Methods
A conjugate vaccine consisting of recombinant Fel d 1 and a virus-like particle derived from the cucumber mosaic virus containing the tetanus toxin–derived universal T-cell epitope tt830-843 (CuMVTT) was used to immunize cats. A first tolerability and immunogenicity study, including a boost injection, was conducted by using the Fel-CuMVTT vaccine alone or in combination with an adjuvant.
Results
The vaccine was well tolerated and had no overt toxic effect. All cats induced a strong and sustained specific IgG antibody response. The induced anti–Fel d 1 antibodies were of high affinity and exhibited a strong neutralization ability tested both in vitro and in vivo. A reduction in the endogenous allergen level and a reduced allergenicity of tear samples, were observed.
Conclusion
Vaccination of cats with Fel-CuMVTT induces neutralizing antibodies and might result in reduced symptoms of allergic cat owners. Both human subjects and animals could profit from this treatment because allergic cat owners would reduce their risk of developing chronic diseases, such as asthma, and become more tolerant of their cats, which therefore could stay in the households and not need to be relinquished to animal shelters
All Author:
Franziska Thoms , Peter Hunziker Melanie Maudrich Gary T. Jennings Monique Vogel Stefanie Haas Andris Zeltins Regina Hofmann-Lehmann Barbara Riond Jonas Grossmann
Antonia Fettelschoss-Gabriel Gabriela Sen Thomas M. Kündig Martin F. BachmannxMartin
——浙大迪迅 译
①人类对猫的过敏通常是由猫的主要过敏原Fel d1引起的，约10%的西方人群中存在猫过敏。目前，没有治疗猫过敏的有效和安全方法。过敏患者通常的应对方法是尽量避免和猫的接触或治疗他们的过敏症状。②我们开发了一种新的策略，用自身主要过敏原Fel d1对猫进行免疫，来治疗人类受试者由Fel d1引起的过敏。③采用重组Fel d 1与来源于黄瓜花叶病毒的病毒样颗粒组成的联合疫苗对猫进行免疫【黄瓜花叶病毒含有破伤风毒素衍生的通用T细胞表位tt830-843 (CuMVTT)】。首次单独或联合使用Fel-CuMVTT疫苗进行耐受性和免疫原性研究，包括增量注射。④该疫苗耐受性良好，没有明显的毒性作用。所有的猫都能诱导出强而持久的特异性IgG抗体反应。诱导的抗fel d1抗体具有较高的亲和力，在体内外均表现出较强的中和能力。内源性变应原水平降低，泪液样本的变应原性降低。⑤给猫接种Fel-CuMVTT可以诱导中和抗体，并可能减少猫主人的过敏症状。人类受试者和动物都可以从这种治疗中获益，因为过敏的猫主人可以降低患慢性疾病(如哮喘)的风险，并变得更能容忍他们的猫，因此这些猫可以呆在家里，不需要被送到动物收容所。
延伸阅读
JACI
[IF:13.1]
Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjectsDOI: https://doi.org/10.1016/j.jaci.2019.01.050
Background
Cat allergy in human subjects is usually caused by the major cat allergen Fel d 1 and is found in approximately 10% of the Western population. Currently, there is no efficient and safe therapy for cat allergy available. Allergic patients usually try to avoid cats or treat their allergy symptoms.
Objective
We developed a new strategy to treat Fel d 1–induced allergy in human subjects by immunizing cats against their own major allergen, Fel d 1.
Methods
A conjugate vaccine consisting of recombinant Fel d 1 and a virus-like particle derived from the cucumber mosaic virus containing the tetanus toxin–derived universal T-cell epitope tt830-843 (CuMVTT) was used to immunize cats. A first tolerability and immunogenicity study, including a boost injection, was conducted by using the Fel-CuMVTT vaccine alone or in combination with an adjuvant.
Results
The vaccine was well tolerated and had no overt toxic effect. All cats induced a strong and sustained specific IgG antibody response. The induced anti–Fel d 1 antibodies were of high affinity and exhibited a strong neutralization ability tested both in vitro and in vivo. A reduction in the endogenous allergen level and a reduced allergenicity of tear samples, were observed.
Conclusion
Vaccination of cats with Fel-CuMVTT induces neutralizing antibodies and might result in reduced symptoms of allergic cat owners. Both human subjects and animals could profit from this treatment because allergic cat owners would reduce their risk of developing chronic diseases, such as asthma, and become more tolerant of their cats, which therefore could stay in the households and not need to be relinquished to animal shelters
All Author:
Franziska Thoms , Peter Hunziker Melanie Maudrich Gary T. Jennings Monique Vogel Stefanie Haas Andris Zeltins Regina Hofmann-Lehmann Barbara Riond Jonas Grossmann
Antonia Fettelschoss-Gabriel Gabriela Sen Thomas M. Kündig Martin F. BachmannxMartin
2019-5-4Artical
创建过敏性疾病的科研、科普知识交流平台，为过敏患者提供专业诊断、治疗、预防的共享平台。
